Half full, it was not me that compared RECAF to DR70, it was Moro. Read one of his answers to questions on Agoracom where he made the statement that DR70 could be used as a predicate for RECAF and could allow RECAF to be FDA approved via a 510k.
Half, RECAF has its problems also. READ Moro's disclaimer and he says the test is affected by infections. From the studies on prostate cancer, RECAF also has problems with benign tumors.
In early 2008, Moro also told me that he had contacted Inverness and told them they could get approval using DR70.
So, there you are Half. Now ask Moro why he would compare RECAF to DR70.
Market Data 
Markets 
AI
